A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
Clinical trial NCT02796352 · TERMINATED
Trial details
- NCT number
- NCT02796352
- Sponsor
- Ahmad Tarhini
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-01
- Primary completion
- 2017-02-16
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.